Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BSLN | Switzerland | CHF | Delayed | |
BSLNz | BATS Europe | CHF | Delayed |
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Alf Gunnar Martin Nicklasson | 68 | 2013 | Independent Non-Executive Director |
Thomas M. Werner | 67 | 2011 | Independent Vice-Chairman |
Domenico Scala | 58 | 2011 | Independent Chairman of the Board |
Nicole Onetto | 70 | 2017 | Independent Non-Executive Director |
Carole A. Sable | 62 | 2023 | Independent Non-Executive Director |
Leonard Kruimer | 66 | 2022 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review